Orogen Royalties Inc
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2020-01-01
- Employees
- 10K
- Market Cap
- -
- Website
- http://www.organon.com
- Introduction
Organon & Co. is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.
To Evaluate Ezetimibe/Simvastatin and Niacin (Extended Release Tablet) in Patients With Type IIa or Type IIb Hyperlipidemia (0653A-091)(COMPLETED)
Phase 3
Completed
- Conditions
- First Posted Date
- 2006-01-04
- Last Posted Date
- 2024-05-16
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 1220
- Registration Number
- NCT00271817
A Study to Assess the Safety and Efficacy of an Investigational Drug in Patients With Osteoarthritis (0663-071)(COMPLETED)
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-12-23
- Last Posted Date
- 2024-08-15
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 528
- Registration Number
- NCT00269191
6-Month Extension Trial of Asenapine With Olanzapine in Negative Symptom Patients Who Completed the Protocol 25543 (25544)(P05777)
- First Posted Date
- 2005-12-14
- Last Posted Date
- 2022-02-09
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 306
- Registration Number
- NCT00265343
Rheumatoid Arthritis Dose Ranging Study (0663-086)(COMPLETED)
- First Posted Date
- 2005-12-12
- Last Posted Date
- 2022-02-09
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 761
- Registration Number
- NCT00264147
Aggrastat to Zocor (AtoZ) - the Use of Two Approved Drugs to Treat Patients Who Have Experienced Chest Pain or a Heart Attack (0733-180)
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-11-10
- Last Posted Date
- 2024-08-15
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 4497
- Registration Number
- NCT00251576
A Study to Evaluate the Safety of an Investigational Drug (Etoricoxib) in Patients With Osteoarthritis (OA) or Rheumatoid Arthritis (RA)(0663-066)
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-11-08
- Last Posted Date
- 2022-02-18
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 23498
- Registration Number
- NCT00250445
Study to Test a Marketed Product in the Treatment of Migraine-associated Nausea
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-11-08
- Last Posted Date
- 2022-02-03
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 346
- Registration Number
- NCT00250458
Montelukast Compared With Placebo and Salmeterol in Exercise-Induced Bronchoconstriction (0476-316)
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-10-28
- Last Posted Date
- 2022-02-02
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 47
- Registration Number
- NCT00245570
Etoricoxib in the Treatment of Osteoarthritis (MK-0663-007)
Phase 2
Completed
- Conditions
- First Posted Date
- 2005-10-20
- Last Posted Date
- 2022-02-18
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 1167
- Registration Number
- NCT00242489
MK0476 Study in Adult Patients With Acute Asthma (0476-322)
- First Posted Date
- 2005-09-30
- Last Posted Date
- 2022-02-02
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 225
- Registration Number
- NCT00229970
© Copyright 2024. All Rights Reserved by MedPath